Clinical trial · Interventional
Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spinal cord trauma and the consequent paraplegia are possibly among the most devastating injuries in soldiers and during spine surgery, and are significant in the medical, social and financial aspects. Limited mobility, the need for assistance in all human activities, shame, and many medical complications related directly to the neural deficits make paraplegia an important target for prevention. Our study will evaluate the efficacy of Minocycline in two different groups: 1. Minimizing the neurological damage among trauma patients. 2. Preventing neurological damage through operation in spinal tumors patients. 2.OBJECTIVES The primary objectives of the trial are to determine: 1. Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients? 2. Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients. 3. Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Spinal Tumors, Trauma Patients, Minocycline. | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Minocycline | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Minocycline, Spinal Tumor patients, quality of life
- interventionNames
- Drug: Minocycline
- type
- EXPERIMENTAL
- label
- Minocycline, Trauma patuents, quality of life
- interventionNames
- Drug: Minocycline
- type
- PLACEBO_COMPARATOR
- label
- Placebo, Trauma patients, quality of life
- interventionNames
- Drug: placebo
- type
- PLACEBO_COMPARATOR
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Trauma patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 1. Inclusion Criteria: 2. Patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 3. Ages: 18 to 65 4. Males - including those involved in active military duty. 5. Females - of child-bearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent. Pregnant women will be excluded from the study. Exclusion Criteria: 1. Complete cord transection, severe head injury, coma, or other disease of the CNS, and spinal injury diagnosed later than 24 hours. 2. Pregnant women (minocycline can cause fetal harm) and children. 3. Lower extremity fractures, mildly reduced consciousness and frail cognitive status will not be considered for exclusion. 4. Patients who will not be enrolled will be listed and reason for non inclusion will be recorded. Spinal tumors: Inclusion Criteria: 1\. Intrathecal extramedullary tumors, vertebral metastases or primary vertebral tumors causing cord compression with or without incomplete cord syndrome. Exclusion criteria: 1.Intramedullary tumors or tumors causing complete cord syndrome \-
References
Publications (0)
Data not yet available